The Investment Council's current calls across every ticker we've researched. Updated 2026-06-04. Click any ticker for the full council reasoning. The Position Sizing column = Adversarial Reviewer + quarter-Kelly. The Next Catalyst column shows the nearest binary thesis-resolver. The Critical Review column shows the weekly critical-research panel verdict: HOLD (clean), CAUTION (watch one specific risk), or → WAIT / → AVOID (recommend bucket move). Critical Review only applies to current BUYs; non-BUYs show n/a.

Buy (16)

Ticker

Verdict

Conviction

Position Sizing

Next Catalyst

Critical Review

One-line reason

Analysis

$ANF

STRONG_BUY

HIGH

TRACKING (0.5-1.0%)

Aug 27 · Q2 earnings

CAUTION (timing)

STRONG_BUY: cheap, growing, zero-debt. Conviction is hot relative to +11.3% target.

$BKNG

STRONG_BUY

HIGH

review pending

Jun 30 · Macro

CAUTION (timing)

STRONG_BUY: 95% transactions perfect, 5% face 7-12 day escalation queues; 15.7x fwd P/E, 6.1% FCF yield, Hormuz shock = temporary

$CHWY

STRONG_BUY

HIGH

TRACKING (0.5-1.0%)

Jun 10 · Q1 earnings

CAUTION (timing)

STRONG_BUY: 14.3x adj. EBITDA (bottom decile), record 83% Autoship, PEG 0.61

$OLLI

STRONG_BUY

HIGH

FULL (1.5-2.0%)

Jun 03 · Q1 earnings

HOLD (clean)

STRONG_BUY: bagholders-paradise multiple, anti-fragile during shopper trade-down

$PINS

STRONG_BUY

HIGH

TRACKING (0.5-1.0%)

Aug 04 · Q2 earnings

HOLD (clean)

STRONG_BUY: shoppable-feed monetisation, ad-load ramp; conviction hot on Q2 guide

$RBLX

BUY

MED

TOKEN (0.25%)

Jun 08 · Product

HOLD (clean)

BUY: verification flywheel + LiveOps; left-tail risk on verification completion

$RCL

BUY

HIGH

review pending

Jul 04 · Product

CAUTION (timing)

BUY: INTACT moat (15.4M loyalty), PERCEIVED_ONLY crisis, REASONABLE valuation post-bookings reset

$SHAK

BUY

MED

TRACKING (0.5-1.0%)

Jul 30 · Q2 earnings

CAUTION (hidden risk)

INTACT moat + HIGHLY_CAPABLE management (Lynch playbook) + REASONABLE multiple + Danny Meyer's ~$2M check

$WING

BUY

MED

TOKEN (0.25%)

Jun 30 · Product

CAUTION (timing)

INTACT moat + PERCEIVED_ONLY crisis (category-wide SSS decline) + REASONABLE valuation at Chipotle parity

$ADBE

STRONG_BUY

HIGH (rev. MED)

TRACKING (0.5-1.0%)

Jun 11 · Q2 earnings

HOLD (clean)

Wide-moat franchise at 10.6x fwd PE; AI fear is narrative not reality

$NOW

BUY

MED

TRACKING (0.5-1.0%)

Jul 29 · Q2 earnings

CAUTION (timing)

INTACT moat + PERCEIVED_ONLY crisis (SaaSpocalypse narrative) + REASONABLE at 9x EV/Sales

$HOOD

BUY

MED (rev. LOW-MED)

TOKEN (0.25%)

Jul 04 · Product

CAUTION (timing)

Crypto hangover, not structural; moat intact, management battle-tested

$STZ

BUY

MED (rev. LOW)

TOKEN (0.25%)

Jun 30 · Q1 earnings

CAUTION (timing)

Premium beer franchise at trough multiples; fear-based demand shock, not brand erosion

$LOW

BUY

MED

TOKEN (0.25%)

Aug 19 · Q2 earnings

HOLD (clean)

INTACT moat (Home Depot duopoly) + PERCEIVED_ONLY crisis (housing freeze + margin compression) + REASONABLE val

$SHOP

BUY

MED

TOKEN (0.25%)

Jul 21 · Product

CAUTION (timing)

INTACT moat (76.8pp B2B/consumer satisfaction gap = merchant lock-in) + REASONABLE val + Jun 8 $5B buyback floor

$SPOT

BUY

MED

TOKEN (0.25%)

Jul 29 · Q2 earnings

HOLD (clean)

INTACT moat (audio network effect + creator economy) + PERCEIVED_ONLY crisis + REASONABLE val

BUY

MED

review pending

Aug 19 · Q2 earnings

Intact moat + perceived crisis; cyclically depressed price with no doom loop

$SHOP

BUY

MED

TOKEN (0.25%)

Jul 21 · Product

Perception gap, not fundamental: 34% growth, expanding payments moat, compressed multiple

$COIN

BUY

MED (rev. LOW)

TOKEN (0.25%)

Jul 04 · Regulatory

CAUTION (timing)

Crypto-cycle repricing, not structural; moat strengthening

Wait (9)

Ticker

Verdict

Conviction

Position Sizing

Next Catalyst

Critical Review

One-line reason

Analysis

$AEO

WAIT

MED

WAIT (0%)

Aug 15 · Ops

n/a

INTACT moat migrating to Aerie (+25% comps) + CHEAP at 0.6x revenue, but two binary unknowns (tariff + AE reboot) resolve in September Q2 print

$CAG

WAIT

MED

WAIT (0%)

Jul 09 · Q4 earnings

n/a

CHEAP at 8.5x fwd P/E (34% peer discount) + 10.3% covered dividend yield, but ERODING moat + new CEO June 1 + July 9 Q4 = decider

$DNUT

WAIT

MED

WAIT (0%)

Aug 06 · Q2 earnings

n/a

CHEAP + asset-light tailwind, but 5.5x leverage + missed top line + uncertain consumer cadence

$GIS

WAIT

MED

WAIT (0%)

Jul 01 · Q4 earnings

n/a

Cheap on the multiple, but ERODING brand-trust + 3.8x leverage + dividend coverage thin

$MKC

WAIT

MED

WAIT (0%)

TBD

n/a

WAIT into the leveraged Kraft Heinz CPG merger; integration risk + standalone earning power both contested

$RVLV

WAIT

MED

WAIT (0%)

Aug 01 · Legal

n/a

Healthy business, internally consistent ~$24.65 target, 5-yr-low EV/EBITDA, WAIT looks soft-BUY-deferred

$WOOF

WAIT

MEDIUM

WAIT (0%)

Jun 03 · Q1 earnings

n/a

Cost work done, growth pivot next, but structural top-line decay + workforce-as-thesis-breaker problem

$WDAY

WAIT

HIGH

WAIT (0%)

Aug 28 · Q2 earnings

n/a

Moat intact + cheap but mid-transition; Q2 earnings is the decider

$TEAM

WAIT

MED

WAIT (0%)

Jul 31 · Q4 earnings

n/a

Moat intact + cheap, but crisis real + capability adequate; wait for Q4 execution evidence

Avoid (25)

Ticker

Verdict

Conviction

Position Sizing

Next Catalyst

Critical Review

One-line reason

Analysis

$BBWI

AVOID

MED

review pending

Jun 12 · Mgmt

n/a

$BMBL

AVOID

MED

review pending

Aug 06 · Q2 earnings

n/a

$CELH

AVOID

MED (rev. LOW)

AVOID (0%)

Aug 11 · Q2 earnings

n/a

Moat eroding (namesake brand growth 100%+ to 5.6% YoY, Kirkland clone at 55% per-can discount). Reviewer pushback 0.48, conviction downgraded one notch.

$CMG

AVOID

MED

review pending

Jul 25 · Q2 earnings

n/a

$COTY

AVOID

MED

review pending

Aug 06 · Q4 earnings

n/a

$CPB

AVOID

MEDIUM

review pending

Jun 08 · Q3 earnings

n/a

$DG

AVOID

MED

review pending

Jul 28 · Legal

n/a

$DKNG

AVOID

MED

review pending

Aug 05 · Q2 earnings

n/a

$ELF

AVOID

MED

review pending

Aug 05 · Q1 earnings

n/a

$EPC

AVOID

MED

review pending

TBD

n/a

$GPRO

AVOID

MED

review pending

Jun 02

n/a

$JACK

AVOID

MED

review pending

Aug 06 · Q3 earnings

n/a

$KMB

AVOID

MED

review pending

Jul 28 · Q2 earnings

n/a

Moat eroding (pricing power -0.5% drag, gross margin gap vs P&G persistent, Huggies reformulation class action active)

$KSS

AVOID

MED

review pending

Jul 15 · Mgmt

n/a

$LCID

AVOID

MED

review pending

Aug 06 · Q2 earnings

n/a

$LULU

AVOID

MED (rev. LOW)

AVOID (0%)

Jun 04 · Q1 earnings

n/a

Moat eroding (three see-through scandals in 24 months, 60% unanswered BBB complaints, Vuori/Alo at 52% overlap). Reviewer pushback 0.42, conviction downgraded one notch.

$NKE

AVOID

MEDIUM

review pending

Jun 25 · Q4 earnings

n/a

$NWL

AVOID

MED

review pending

Jul 31 · Q2 earnings

n/a

$PLNT

AVOID

MED

review pending

Aug 06 · Q2 earnings

n/a

$PTON

AVOID

MED

review pending

Aug 07 · Q4 earnings

n/a

$SNAP

AVOID

MED

AVOID (0%)

Jun 16 · Product

n/a

Moat eroding (NA DAU bleeding 98M to 92M, eCPMs -12%, ad-business growth +3% vs META +33%). Reviewer pushback 0.28, conviction held.

$W

AVOID

MED

review pending

TBD

n/a

$WHR

AVOID

MED

TOKEN (0.25%)

Jun 30

n/a

$INTUAVOIDMED (rev. LOW)AVOID (0%)Aug 28 · Q4 earningsn/aMoat eroding (TurboTax DIY units declining 2%, AI-native competitors offering free IRS-authorized filing). Reviewer pushback 0.62, conviction downgraded one notch.link

$PYPL

AVOID

MED

AVOID (0%)

Aug 01 · Q2 earnings

n/a

Moat eroding: branded checkout 1-2%, Apple Pay 55% mobile wallet share; cheap at 8.7x but value trap until checkout inflects

How sizing works

Every BUY/WAIT/AVOID goes through a single Adversarial Reviewer after the Investment Council. The reviewer outputs a pushback probability (0.00-1.00). final conviction = council_conviction x (1 - pushback) → quarter-Kelly band. Verdicts are never flipped by the Adversarial Reviewer unless pushback >= 0.80. BUYs additionally go through the weekly Critical Review panel (4 asymmetric frames: Entry-Timing, Insider/Smart-Money, Hidden-Risk, Crowdedness). The Critical Review only flags HOLD / CAUTION / DEMOTE — it does NOT move rows automatically. The publisher manually accepts or rejects a DEMOTE recommendation.

First 17 reviewed tickers in the Adversarial Reviewer batch: 0 flipped. Two AVOIDs (CELH 0.48, LULU 0.42) drew enough pushback to warrant a one-notch conviction downgrade (MED to LOW) without changing the verdict itself.

Keep reading